4 results on '"Hernandez Hernandez I"'
Search Results
2. Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
- Author
-
Irene Hernandez, J. Hernando, Oriol Mirallas, Elena Martínez-Sáez, Anas Chaachou, A. Garcia-Alvarez, Betina Biagetti, Francesca Filippi-Arriaga, Anton Aubanell, Jaume Capdevila, Institut Català de la Salut, [Mirallas O, Garcia-Alvarez A, Hernando J, Capdevila J] Servei d’Oncologia Mèdica, Unitat de Tumors Gastrointestinals i Endocrins, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Filippi-Arriaga F] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Hernandez Hernandez I, Biagetti B] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Aubanell A] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Chaachou A, Martínez-Saez E] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Hipòfisi - Tumors - Tractament ,Adenoma ,Male ,medicine.medical_specialty ,Side effect ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,Case Report ,Disease ,temozolomide ,aggressive pituitary tumors ,Adenoma - Tractament ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,Quimioteràpia combinada ,Diseases of the endocrine glands. Clinical endocrinology ,Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Adenoma [DISEASES] ,Nelson Syndrome ,Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Pituitary Neoplasms::ACTH-Secreting Pituitary Adenoma::Nelson Syndrome [DISEASES] ,Capecitabine ,Endocrinology ,Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Neoplasm Invasiveness ,Pituitary Neoplasms ,neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::adenoma [ENFERMEDADES] ,Adverse effect ,Chemotherapy ,Temozolomide ,Nelson’s syndrome ,business.industry ,capecitabine ,Pituitary tumors ,Nelson's syndrome ,terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Middle Aged ,medicine.disease ,RC648-665 ,Surgery ,Tumor Burden ,Treatment Outcome ,neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias hipofisarias::adenoma hipofisario secretor de ACTH::síndrome de Nelson [ENFERMEDADES] ,Spain ,business ,medicine.drug - Abstract
Agressive pituitary tumors; Capecitabine; Temozolomide Tumores hipofisarios agresivos; Capecitabina; Temozolomida Tumors hipofisaris agressius; Capecitabina; Temozolomida Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.
- Published
- 2021
3. Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson's Syndrome: A Case Report.
- Author
-
Mirallas O, Filippi-Arriaga F, Hernandez Hernandez I, Aubanell A, Chaachou A, Garcia-Alvarez A, Hernando J, Martínez-Saez E, Biagetti B, and Capdevila J
- Subjects
- Adenoma complications, Adenoma pathology, Capecitabine administration & dosage, Humans, Male, Middle Aged, Nelson Syndrome complications, Neoplasm Invasiveness, Pituitary Neoplasms complications, Pituitary Neoplasms pathology, Spain, Temozolomide administration & dosage, Treatment Outcome, Tumor Burden, Adenoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Nelson Syndrome drug therapy, Pituitary Neoplasms drug therapy
- Abstract
Nelson's syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing's disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson's syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Mirallas, Filippi-Arriaga, Hernandez Hernandez, Aubanell, Chaachou, Garcia-Alvarez, Hernando, Martínez-Saez, Biagetti and Capdevila.)
- Published
- 2021
- Full Text
- View/download PDF
4. SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high-fat-diet-fed mice.
- Author
-
Zadjali F, Santana-Farre R, Vesterlund M, Carow B, Mirecki-Garrido M, Hernandez-Hernandez I, Flodström-Tullberg M, Parini P, Rottenberg M, Norstedt G, Fernandez-Perez L, and Flores-Morales A
- Subjects
- Animals, Interferon-gamma metabolism, Interleukin-6 metabolism, Lipid Metabolism, Liver metabolism, Male, Mice, Mice, Knockout, NF-kappa B metabolism, Toll-Like Receptor 4 antagonists & inhibitors, Triglycerides metabolism, Diet, High-Fat, Fatty Liver prevention & control, Insulin Resistance physiology, Suppressor of Cytokine Signaling Proteins deficiency, Suppressor of Cytokine Signaling Proteins physiology
- Abstract
Hepatic steatosis is a prominent feature in patients with growth hormone (GH) deficiency. The ubiquitin ligase SOCS2 attenuates hepatic GH signaling by inhibiting the Janus kinase 2 (JAK2)-signal transducer and activator of transcription 5b (STAT5b) axis. Here, we investigated the role of SOCS2 in the development of diet-induced hepatic steatosis and insulin resistance. SOCS2-knockout (SOCS2(-/-)) mice and wild-type littermates were fed for 4 mo with control or high-fat diet, followed by assessment of insulin sensitivity, hepatic lipid content, and expression of inflammatory cytokines. SOCS2(-/-) mice exhibited increased hepatic TG secretion by 77.6% (P<0.001) as compared with wild-type control mice and were protected from high-fat-diet (HFD)-induced hepatic steatosis, showing 49.3% (P<0.01) reduction in liver TG levels compared to HFD-fed wild-type littermates. In contrast, we found that HFD-triggered attenuation of systemic insulin sensitivity was more marked in SOCS2(-/-) mice. Livers from the HFD-fed SOCS2(-/-) mice showed increased NF-κB activity as well as elevated expression of genes for the inflammatory cytokines IFN-γ and IL-6. An inhibitory role of SOCS2 on Toll-like receptor 4 signaling was demonstrated in macrophages obtained from the SOCS2(-/-) and wild-type mice. This study identified SOCS2 as an important regulator of hepatic homeostasis under conditions of high-fat dietary stress.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.